These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 26769142)
1. Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma. Hung NA; Eiholzer RA; Kirs S; Zhou J; Ward-Hartstonge K; Wiles AK; Frampton CM; Taha A; Royds JA; Slatter TL Mod Pathol; 2016 Mar; 29(3):212-26. PubMed ID: 26769142 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Lötsch D; Ghanim B; Laaber M; Wurm G; Weis S; Lenz S; Webersinke G; Pichler J; Berger W; Spiegl-Kreinecker S Neuro Oncol; 2013 Apr; 15(4):423-32. PubMed ID: 23393205 [TBL] [Abstract][Full Text] [Related]
3. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas. Lee JC; Jeng YM; Liau JY; Tsai JH; Hsu HH; Yang CY Mod Pathol; 2015 Aug; 28(8):1064-73. PubMed ID: 26022452 [TBL] [Abstract][Full Text] [Related]
4. MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication. Zhou J; Reddy MV; Wilson BKJ; Blair DA; Taha A; Frampton CM; Eiholzer RA; Gan PYC; Ziad F; Thotathil Z; Kirs S; Hung NA; Royds JA; Slatter TL AJNR Am J Neuroradiol; 2018 Feb; 39(2):252-259. PubMed ID: 29191871 [TBL] [Abstract][Full Text] [Related]
5. The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. Royds JA; Al Nadaf S; Wiles AK; Chen YJ; Ahn A; Shaw A; Bowie S; Lam F; Baguley BC; Braithwaite AW; MacFarlane MR; Hung NA; Slatter TL PLoS One; 2011; 6(10):e26737. PubMed ID: 22046342 [TBL] [Abstract][Full Text] [Related]
6. Effect of silencing key proteins in telomerase mechanism and alternative lengthening of telomeres mechanism in laryngeal cancer cells. Xu Y; Wang X; Chen SM; Chen C; Wang Y; Xiao BK; Tao ZZ Am J Otolaryngol; 2016; 37(6):552-558. PubMed ID: 27726944 [TBL] [Abstract][Full Text] [Related]
7. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247 [TBL] [Abstract][Full Text] [Related]
8. Telomere length modulation in human astroglial brain tumors. La Torre D; Conti A; Aguennouz MH; De Pasquale MG; Romeo S; Angileri FF; Cardali S; Tomasello C; Alafaci C; Germanò A PLoS One; 2013; 8(5):e64296. PubMed ID: 23691191 [TBL] [Abstract][Full Text] [Related]
9. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Hakin-Smith V; Jellinek DA; Levy D; Carroll T; Teo M; Timperley WR; McKay MJ; Reddel RR; Royds JA Lancet; 2003 Mar; 361(9360):836-8. PubMed ID: 12642053 [TBL] [Abstract][Full Text] [Related]
12. Telomere maintenance in sarcomas. Johnson JE; Broccoli D Curr Opin Oncol; 2007 Jul; 19(4):377-82. PubMed ID: 17545803 [TBL] [Abstract][Full Text] [Related]
13. Alternative lengthening of telomeres (ALT) and chromatin: is there a connection? Nittis T; Guittat L; Stewart SA Biochimie; 2008 Jan; 90(1):5-12. PubMed ID: 17935854 [TBL] [Abstract][Full Text] [Related]
14. Telomerase activity and alterations in telomere length in human brain tumors. Hiraga S; Ohnishi T; Izumoto S; Miyahara E; Kanemura Y; Matsumura H; Arita N Cancer Res; 1998 May; 58(10):2117-25. PubMed ID: 9605755 [TBL] [Abstract][Full Text] [Related]